EDOC:AU:AU-BetaShares Digital Health and Telemedicine ETF (AUD)

ETF | Others |

Last Closing

USD 10.56

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.55 (+0.53%)

USD 17.87B
IVV:AU iShares Core S&P 500 AUD

-0.05 (-0.08%)

USD 11.24B
VGS:AU Vanguard MSCI International Sh..

-0.13 (-0.09%)

USD 10.01B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.01 (+0.02%)

USD 7.10B
IOZ:AU Ishares Core S&P/Asx 200

+0.18 (+0.53%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

+0.41 (+0.54%)

USD 5.57B
VTS:AU Vanguard US Total Market Share..

-1.20 (-0.25%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.19 (-0.37%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.01 (+0.02%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.73 (+0.52%)

USD 4.72B

ETFs Containing EDOC:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.23% 72% C 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.23% 63% D 57% F
Trailing 12 Months  
Capital Gain 12.34% 58% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.34% 45% F 62% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.96% 16% F 36% F
Dividend Return -0.96% 14% F 34% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.46% 66% D+ 92% A
Risk Adjusted Return -11.31% 14% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.